ScreenerHero

HYL Hyloris Pharmaceuticals SA

EBR · BE · Healthcare · Biotechnology · hyloris.com
3.910EUR-4.17%Mkt Cap: 119.00M $P/E: —

Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap119.00M USD
Enterprise Value105.93M USD
Revenue (TTM)10.68M USD
Gross Profit7.42M USD
Net Income (TTM)-6.88M USD
Revenue/Share0.35 EUR
Last Price3.910 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees54
CountryBE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-19.55
PEG—
EV/EBITDA-16.67
EV/Revenue9.92
P/S11.14
P/B4.20
EPS (TTM)-0.17
EPS (Forward)-0.20
52W Range
3.8102% of range8.400
52W High8.400 EUR
52W Low3.810 EUR
Profitability
Gross Margin94.74%
Oper. Margin-27.05%
EBITDA Margin-59.48%
Profit Margin-87.89%
ROE-23.92%
ROA-18.99%
Growth
Revenue Growth56.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.60M USD
CapEx (TTM)683.70K USD
FCF Margin-89.50%
FCF Yield-8.03%
Net Debt-7.91M USD
Net Debt/EBITDA1.24
Balance Sheet
Debt/Equity0.06
Current Ratio4.82
Quick Ratio4.64
Book Value/Sh0.93 EUR
Cash/Share0.33 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.23 EUR
Upside (mean)+187.3%
Target Range6.000 EUR – 17.20 EUR
6.000+187.3% to mean17.20
# Analysts3
Ownership
Shares Out.28.00M
Float24.76M
Insiders56.62%
Institutions0.00%
Technical
SMA 504.430 (-11.7%)
SMA 2005.474 (-28.6%)
Beta0.64
S&P 52W Chg16.45%
Avg Vol (30d)3.25K
Avg Vol (10d)5.50K
Technical Indicators
RSI (14)33.3
MACD-0.0778
MACD Signal-0.0523
MACD Hist.-0.0255
BB Upper4.535 EUR
BB Middle4.250 EUR
BB Lower3.964 EUR
BB Width13.43%
ATR (14)0.1444 EUR
Vol Ratio (20d)3.00x